TrialHeadache2020

Eptinezumab Demonstrated Efficacy in Sustained Prevention of Episodic and Chronic Migraine Beginning on Day 1 After Dosing.

David W Dodick et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.